Simplification of HAART therapy on ambulatory HIV patients in Malaysia

Keywords: Antiretroviral Therapy, Highly Active, Emtricitabine, Tenofovir, Benzoxazines, Anti-Retroviral Agents, Drug Combinations, CD4 Lymphocyte Count, Viral Load, Malaysia

Abstract

Objective:  Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV.

Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months.

Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group.

Conclusion: Management of  HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.

Downloads

Download data is not yet available.

References

1. World Health Organization. HIV/AIDS. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/ (accessed 20.01.16).

2. Ministry of Health Malaysia. Ungass Country Progress Report. 2010. Available at: http://www.unaids.org/sites/default/files/en/dataanalysis/knowyourresponse/countryprogressreports/2010countries/malaysia_2010_country_progress_report_en.pdf (accessed 13.12.15).

3. Ministry of Health Malaysia. National Strategic Plan On HIV and AIDS 2011-2015. http://www.moh.gov.my/images/gallery/Report/NSP_AIDS_2011_2015.pdf (accessed 22.02.16).

4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.

5. National HIV/AIDS Treatment Registry Malaysia. The first report of the national HIV/AIDS treatment registry 2003. Clinical Research Centre, Kuala Lumpur; 2005.

6. Ministry of Health Malaysia. Guidelines For The Management Of Adult HIV Infection With Antiretroviral Therapy. Available at: http://www.moh.gov.my/images/gallery/garispanduan/hivguidelines.pdf (accessed 10.02.16).

7. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18(8):682-689.

8. Gakhar H, Kamali A, Holodniy M. Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature. Drugs. 2013;73(7):651-672. doi: 10.1007/s40265-013-0040-4

9. Hawkins C, Murphy R. Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007;21(8):1041-1042.

10. Saleem F, Hassali MA, Shafie AA, Awad GA, Atif M, ul Haq N, Aljadhey H, Farooqui M. Does treatment adherence correlates with health-related quality of life? Findings from a cross-sectional study. BMC Public Health. 2012;12:318. doi: 10.1186/1471-2458-12-318

11. Saleem F, Hassali MA, Shafie AA, Awad AG, Bashir S. Association between Knowledge and Drug Adherence in Patients with Hypertension in Quetta, Pakistan. Trop J Pharm Res. 2011;10(2):125-132.

12. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. doi: 10.1002/14651858.CD000011.pub3

13. Carballo E, Cadarso-Suárez C, Carrera I, Fraga J, de la Fuente J, Ocampo A, Ojea R, Prieto A. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004;13(3):587-599.

14. Sakthong P, Schommer JC, Gross CR, Prasithsirikul W, Sakulbumrungsil R. Health Utilities in Patients with HIV/AIDS in Thailand. Value Health. 2009;12(2):377-384. doi: 10.1111/j.1524-4733.2008.00440.x

15. Krejci RV, Morgan DW. Determining sample size for research activities. Educ Psychol Meas 1970;30: 607-610.

16. World Health Organization (WHO). On The Use Of Antiretroviral Drugs For Treating And Preventing HIV Infection. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf (accessed on 14.01.16).

17. Ministry of Health Malaysia, National Pharmaceutical Control Bureau (NPCB). Report on Suspected Adverse Drug Reaction. Available at: http://bpfk.moh.gov.my/index.php/adr-reporting (accessed 20.04.16).

18. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-354.

19. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: Final response. J Clin Epidemiol. 2011;64(3):255-257. doi: 10.1016/j.jclinepi.2010.09.002

20. EQ-5D User Guide. Basic information on how to use the EQ-5D-3L instrument . Available at: http://www.euroqol.org/fileadmin/user_upload/documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf (accessed 10.05.15).

21. World Health Organization. WHO issues new HIV recommendations calling for earlier treatment. Available at: http://www.who.int/mediacentre/news/releases/2013/new_hiv_recommendations_20130630/en/ (accessed on 14.04.2016).

22. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, Smith DK; HERS STUDY. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124-131.

23. Gokarn A, Narkhede MG, Pardeshi GS, Doibale MK. Adherence to antiretroviral therapy. J Assoc Physicians India. 2012;60:16-20.

24. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51(2):163-174. doi: 10.1097/QAI.0b013e3181a572cf

25. Green LW, Kreuter MW. Health program planning: An educational and ecological approach, fourth Ed. McGraw-Hill New York; 2005.

26. Hasanah CI, Zaliha AR, Mahiran M. Factors influencing the quality of life in patients with HIV in Malaysia. Qual Life Res. 2011;20(1):91-100. doi: 10.1007/s11136-010-9729-y

27. Ghailan K, Jusoh A, Rizal M, Ezat S, Ibrahim F, Halil J, Aljunid S. Impact of HIV/Aids Morbidity on Households Economy in Malaysia. Global J Health Sci. 2010;2 (2):142-153. doi: 10.5539/gjhs.v2n2p142

28. Jiamsakul A, Kumarasamy N, Ditangco R, Li PC, Phanuphak P, Sirisanthana T, Sungkanuparph S, Kantipong P, K C Lee C, Mustafa M, Merati T, Kamarulzaman A, Singtoroj T, Law M; TREAT Asia Studies to Evaluate Resistance Monitoring Study (TASER-M). Factors associated with suboptimal adherence to antiretroviral therapy in Asia. J Int AIDS Soc. 2014;17:18911. doi: 10.7448/IAS.17.1.18911

29. Ndubuka NO, Ehlers VJ. Adult patients’ adherence to antiretroviral treatment: A survey correlating pharmacy refill records and pill counts with immunological and virological indices. Int J Nurs Stud. 2011;48(11):1323-1329. doi: 10.1016/j.ijnurstu.2011.04.006

30. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189-199.

31. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, Gori A, Suter F, Maggiolo F. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV infected subjects. Patient Prefer Adherence. 2010;4:115-125.

32. Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297-1307. doi: 10.1093/cid/ciu046

33. Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. J Int AIDS Soc. 2008;10(8):196. doi: 10.1186/1758-2652-10-8-196

34. Astuti N, Maggiolo F. Single-Tablet Regimens in HIV Therapy. Infect Dis Ther. 2014;3(1):1-17. doi: 10.1007/s40121-014-0024-z

35. Clay PG, Taylor TA, Glaros AG, McRae M, Williams C, McCandless D, Oelklaus M. “One pill, once daily”: what clinicians need to know about Atripla. Ther Clin Risk Manag. 2008;4(2):291-302.

36. Fielden SJ, Rusch ML, Yip B, Wood E, Shannon K, Levy AR, Montaner JS, Hogg RS. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care (Chic). 2008;7(5):238-244. doi: 10.1177/1545109708323132

37. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564-573.

38. Horberg MA, Klein DB. An update on the use of Atripla in the treatment of HIV in the United States. HIV AIDS (Auckl). 2010;2:135-140

39. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484-488. doi: 10.1086/596482

40. Wouters E, Van Loon F, Van Rensburg D, Meulemans H. State of the ART: clinical efficacy and improved quality of life in the public antiretroviral therapy program, Free State province, South Africa. AIDS Care. 2009;21(11):1401-1411. doi: 10.1080/09540120902884034

41. Mathews WC1, May S. EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes. 2007;5:5.

42. Butt M, Ali AM, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomized controlled study. Saudi Pharm J. 2016; 24(1):40-48. doi: 10.1016/j.jsps.2015.02.023

43. Hanna DB, Hessol NA, Golub ET, Cocohoba JM, Cohen MH, Levine AM, Wilson TE, Young M, Anastos K, Kaplan RC. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(5):587-596. doi: 10.1097/QAI.0000000000000082
Published
2016-12-16
How to Cite
1.
Velvanathan T, Islahudin F, Sim BL, Taha NA. Simplification of HAART therapy on ambulatory HIV patients in Malaysia. Pharm Pract (Granada) [Internet]. 2016Dec.16 [cited 2019Jul.17];14(4):830. Available from: https://pharmacypractice.org/journal/index.php/pp/article/view/830
Section
Original Research